PharmAsia News Business Bulletin
This article was originally published in Scrip
Executive Summary
A regular roundup of commercial stories appearing in Scrip's sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence on the Asian marketplace.
You may also be interested in...
India Clears Off-The-Shelf Stem Cell Therapy for Buerger's
Stempeutics Research has been granted limited approval to make and sell the first allogeneic cell therapy product for Buerger’s Disease in India. The stem cell therapy, which was granted orphan drug designation by the EMA last year, may hold potential in certain additional indications as well.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.